I agree that there are some concerns in some of the numbers, but I am also happy to accept the explanation from the mgmt team. If my memory is correct, CSL expenses R&D and with the cost of some of the Phase 3 trials being paid now, I can understand some of the margin pressure. BUT - watching that it does not "become a habit" will be important.
HT1
News: CSL UPDATE 1-CSL's half-year profit beats estimates on robust blood plasma collections, page-11
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$305.47 |
Change
1.060(0.35%) |
Mkt cap ! $147.6B | |||
| Open | High | Low | Value | Volume |
| $303.88 | $307.33 | $303.80 | $141.3M | 462.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 750 | $305.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $305.53 | 1372 | 3 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |